Posledná aktualizácia :
19/11/2024
analgetikum   Remifentanil hydrochloride  
Injekcia
Stabilita roztokov Stabilita v zmesiach Faktory ovplyvňujúce stabilitu Kompatibility spôsob podania Odkazy na literatúru PDF
   Chemický vzorec  

Obchodný názov   Obchodný názov     

Obchodné názvy sú orientačné, a zloženie pomocných látok sa môže líšiť v závislosti od krajiny a výrobcu.

Fenburol Čile, Juhoafrická republika
Proximicil Mexiko
Redormin Argentína
Remicit Argentína
Remifas Ekvádor
Remifentanil Belgicko, Island, Kanada, Nemecko, Nórsko, nový Zéland, Rumunsko
Remifentanilo Argentína, Portugalsko, Španielsko
Remiflo Argentína
Remimed Nemecko
Restinil Argentína, Ekvádor
Sagal Argentína
Ultiva Austrália, Belgicko, Čile, Dánsko, Egypt, Ekvádor, Fínsko, Francúzsko, Grécko, Holandsko, Irán, Írsko, Kolumbia, Luxembursko, Maďarsko, Malajzia, Nemecko, Nórsko, nový Zéland, peru, Poľsko, Portugalsko, Rakúsko, Rumunsko, Saudská Arábia, Španielsko, Spojené štáty Americké, Švajčiarsko, Švédsko, Taliansko, Tunisko, Turecko, Veľká Británia, Venezuela
Odkazy na literatúru   Injekcia   Odkazy na literatúru : Remifentanil hydrochloride  
Typ Publikácia
59 Časopis Trissel LA, Gilbert DL, Martinez JF, Kim MC.
Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
921 Časopis Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
1506 Časopis Lopez-Cabezas C, Guerrero L, Molas G, Anglada H, Soy D.
Physicochemical compatibility of high concentration drugs usually Y-site administered in intensive care units.
EJHP 2015 ;22:107-112.
1508 Časopis Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F.
Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU.
EJHP 2015 ;22:123-124.
1712 Časopis Trissel LA, Saenz CA.
Compatibility screening of Precedex during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 230-233.
1803 Časopis Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2003 ; 60: 80-85.
1925 Časopis Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
2141 Časopis Barinian N, Chanteux H, Viaene E, Servais H, Tulkens PM.
Stability and compatibility study of cefepime in comparaison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units.
J Antimicrob Chemother 2003 ; 51: 651-658.
2269 Časopis Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2325 Časopis Nemec K, Germ E, Schulz-Siegmund M, Ortner A.
The effect of nimodipine, fentanyl and remifentanil intravenous products on the stability of propofol emulsions.
Pharmazie 2009 ; 64, 2: 94-97.
3176 Poster Humbert Delaloye V, Berger M, Voirol P, Pannatier A.
Compatibilité du Remifentanil avec d'autres médicaments injectables : influence du soluté.
16èmes JFSPH, Sion, 18-19 novembre 2010
3249 Časopis Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3294 Časopis Humbert-Delaloye V, Berger M, Voirol P, Pannatier A.
In vitro compatibility of remifentanil hydrochloride and sufentanil citrate with selected drugs
EJHP 2012 ; 19: 57-64.
3372 Časopis Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S.
Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine.
Rev Bras Anestesiol 2013 ; 63, 1: 163-166.
3504 Laboratórium Parecoxib (Dynastat®) - Summary of Product Characteristics
Pfizer 2012
3519 Laboratórium Remifentanil hydrochloride(Ultiva®) - Summary of Product Characteristics
Glaxo Smith Kline 2011
3781 Časopis Humbert-Delaloye V, Berger-Gryllaki M, Voirol P, Testa B, Pannatier A
Screening for physicochemical incompatibilities of intravenous drugs in intensive care units: the case of monobasic potassium phosphate and furosemide.
EJHP 2015 ;22:1 56-58
3823 Časopis Juan E.P, Palau M.M, Cerd? S.A, Rubert M.A, Nicolau B.R.
Compatibilité physique de médicaments administrés dans l’unité de soins intensifs
Pharmactuel 2015 ; 48, 3 : 146-152.
4011 Časopis Gersonde F, Eisend S, Haake N, Kunze T.
Physicochemical compatibility and emulsion stability of propofol with commonly used analgesics and sedatives in an intensive care unit.
EJHP 2016 2016;0:1-11
4183 Poster Hook R, Riss V, Scharrer E, Law S, Walker S.E.
Stability if 4 and 10 mcg/mL Remifentanil Solutions Stored in Syringes at Room Temperature (23°C).
Professional Practice Conference - the Canadian So 2018
4192 Časopis Bourdon F, Simon N, Lannoy D, Berneron C, D?caudin B, Reumaux L, Duhamel A, Richart P, Odou P.
Quality control and stability of ketamine, remifentanil and sufentanil syringes in a pediatric operating theater.
Pediatric Anesthesia 2018
4231 Poster Roxanne Hook, Vera Riss, Erica Scharrer, Shirley Law and Scott E. Walker
Stability of 4 and 10 mcg/mL Remifentanil Solutions Stored in Syringes at Room Temperature (23°C)
Professional Practice Conference - Canadian Societ 2018
4331 Časopis Nilsson N, Nezvalova-Henriksen K, Tho I.
Emulsion Stability of Different Intravenous Propofol Formulations in Simulated Co-Administration with Remifentanil Hydrochloride.
Pharmaceutical Technology in Hospital Pharmacy 2019
4389 Časopis Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G.
Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine.
Pharmactuel 2019 ;52,4:206-213
4501 Časopis Henkel E, Vella R, Behan K, Austin D, Kruger P, Fenning A.
The effect of concentration, reconstitution solution and pH on the stability of a remifentanil hydrochloride and propofol admixture for simultaneous co-infusion.
BMC Anesthesiology 2020 ;20:283.
4650 Laboratórium Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021.
Advanz Pharma 2021
4698 Časopis Ayari G, D'Huart E, Vigneron J, Demoré B.
Y-site compatibility of intravenous medications commonly used in intensive care units : laboratory tests on 75 mixtures involving nine main drugs.
Pharmaceutical Technology in Hospital Pharmacy 2022
4723 Časopis Kondo M, Yoshida N, Yoshida M, Tanaka C, Tagami T, Horik K, Sugaya K, Takase H
Physical compatibility of remimazolam with opioid analgesics, sedatives, and muscle relaxants during simulated Y-site administration.
Am J Health-Syst Pharm 2022 https://doi.org/10.1093/a
4742 Časopis Macoviciuc M, Nguyen C, Forest J-M, Leclair G.
Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y.
Pharmactuel 2022 ; 55, 4: 247-255.

  Mentions Légales